| Geng, Songmei |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Recruiting | 3 | 702 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 05/24 | 10/25 | | |
NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment |
|
|
| Recruiting | 2 | 200 | RoW | LP-003, Placebo, Omalizumab | Longbio Pharma | Chronic Spontaneous Urticaria | 01/25 | 01/25 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China |
|
|
| Not yet recruiting | N/A | 130 | RoW | No intervention | Takeda | Hereditary Angioedema (HAE) | 08/25 | 08/25 | | |
| Xu, Tianhong |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Recruiting | 3 | 702 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 05/24 | 10/25 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
